Group 1 - The core point of the article is that North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating that the product meets the basic entry requirements for centralized procurement [1] - The approval of injectable vancomycin hydrochloride (0.5g) demonstrates that the product's efficacy is equivalent to that of the original research product, enhancing the company's product structure in the field of anti-infection [1] - This new product complements the existing product, Vanxun (injectable deacetyl vancomycin), thereby improving the company's offerings in the anti-infection sector [1]